ALLMedicine Cardiovascular Risk Reduction Center

May 3rd, 2020 - The LEADER trial (ClinicalTrials.gov reg. no. NCT01179048) demonstrated a reduced risk of cardiovascular (CV) events for patients with type 2 diabetes who received the glucagon-like peptide 1 receptor agonist liraglutide versus placebo. The mechan...

Apr 29th, 2020 - Inflammation as a cardiovascular risk factor has attracted increasing attention . The current standard of care for decreasing the occurrence of cardiovascular events includes controlling risk factors such as hypertension and maximizing the lowerin...

Apr 25th, 2020 - This commentary builds on the unhealthy lifestyle habits, population health, risk factors as harbingers of cardiovascular disease, current provider counseling practices, assessing patient readiness to change, and research-based interventions to fa...

Apr 21st, 2020 - Relates to: 'Bedtime Hypertension Treatment Improves Cardiovascular Risk Reduction: Hygia Chronotherapy Trial'.|2020||

Apr 20th, 2020 - Introduction: Type 2 diabetes mellitus and cardiovascular disease contribute to significant morbidity, mortality, and health-care resource expenditure. The pathophysiological and clinical associations between diabetes and cardiovascular disease ha...

Mar 16th, 2019 - Although there has been substantial improvement in atherosclerotic cardiovascular disease (ASCVD) outcomes in recent decades, ASCVD remains the leading cause of morbidity and mortality globally (S1- 1–S1-3). In the United States, it is also the le...

Feb 1st, 2019 - Statin therapy has been shown to reduce major vascular events and vascular mortality in a wide range of individuals, but there is uncertainty about its efficacy and safety among older people. We undertook a meta-analysis of data from all large sta...

Jan 21st, 2019 - Question: What is the association of aspirin use with cardiovascular events and bleeding events in individuals without cardiovascular disease? Findings: In this meta-analysis of 13 trials with 164 225 participants without cardiovascular disease, a...

Jan 5th, 2019 - After the holidays, often as part of a New Year’s resolution, it is common for people to think about changing to a healthier diet. One option is the Mediterranean diet, which was recently named by U.S. News & World Report as the top overall diet, ...

Dec 17th, 2018 - Chronic kidney disease (CKD) is diagnosed by the persistent presence of elevated urinary albumin excretion (albuminuria), low estimated glomerular filtration rate (eGFR), or other manifestations of kidney damage (1,2). In this section, the focus w...

May 3rd, 2020 - The LEADER trial (ClinicalTrials.gov reg. no. NCT01179048) demonstrated a reduced risk of cardiovascular (CV) events for patients with type 2 diabetes who received the glucagon-like peptide 1 receptor agonist liraglutide versus placebo. The mechan...

Apr 29th, 2020 - Inflammation as a cardiovascular risk factor has attracted increasing attention . The current standard of care for decreasing the occurrence of cardiovascular events includes controlling risk factors such as hypertension and maximizing the lowerin...

Apr 25th, 2020 - This commentary builds on the unhealthy lifestyle habits, population health, risk factors as harbingers of cardiovascular disease, current provider counseling practices, assessing patient readiness to change, and research-based interventions to fa...

Apr 21st, 2020 - Relates to: 'Bedtime Hypertension Treatment Improves Cardiovascular Risk Reduction: Hygia Chronotherapy Trial'.|2020||

Apr 20th, 2020 - Introduction: Type 2 diabetes mellitus and cardiovascular disease contribute to significant morbidity, mortality, and health-care resource expenditure. The pathophysiological and clinical associations between diabetes and cardiovascular disease ha...

Feb 27th, 2020 - This transcript has been edited for clarity. Today I'm going to continue my overview of the 2020 American Diabetes Association (ADA) Standards of Medical Care in Diabetes. Pharmacologic approaches to the management of glycemia in patients with typ...

Dec 17th, 2019 - The newly approved US indication for icosapent ethyl (Vascepa, Amarin) is broadly in line with the entry criteria for the REDUCE-IT trial and includes a large high-risk primary prevention population, as well as those with established cardiovascula...

Dec 13th, 2019 - Icosapent ethyl (Vascepa) has gained an indication from the Food and Drug Administration for reduction of cardiovascular events in patients with high triglycerides who are at high risk for cardiovascular events. Olivier Le Moal/Getty Images It is.

Dec 12th, 2019 - The Food and Drug Administration (FDA) has approved icosapent ethyl (Vascepa, Amarin) to reduce the risk for cardiovascular (CV) events in people with elevated triglyceride levels and either established CV disease or diabetes with other CV risk fa...

Dec 12th, 2019 - So then, “why is there the view that women with type 2 diabetes need more aggressive cardiovascular risk reduction than men with diabetes? “It probably comes back to confusion based on absolute risk versus a comparison of relative risk within each.